Effect of GnRH analogue on height potential in patients with severe growth hormone insensitivity syndrome treated with IGF-I

Journal of Pediatric Endocrinology and Metabolism

Volumn 24, Issue 11-12, 2011, Pages 983-988

  Kholy, Mohamed El ^a   Elsedfy, Heba H ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

GnRH analogue therapy; growth hormone insensitivity; IGF I therapy; Laron syndrome

Indexed keywords

GONADORELIN; SOMATOMEDIN C;

ADOLESCENT; ARTICLE; BODY HEIGHT; BONE DENSITY; BONE MATURATION; CASE REPORT; CHILD; CHILDHOOD DISEASE; COMPARATIVE EFFECTIVENESS; FEMALE; GROWTH RATE; HORMONAL THERAPY; HORMONE RESISTANCE; HUMAN; LARON SYNDROME; MALE; PUBERTY; SCHOOL CHILD;

BODY HEIGHT; CHILD; FEMALE; GONADOTROPIN-RELEASING HORMONE; GROWTH CHARTS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LARON SYNDROME; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 83655172874     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/JPEM.2011.348     Document Type: Article

References (21)

1. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004;89:1031-44. (Pubitemid 38368385)
2. Illig R, Prader A, Ferrandez A, Zachmann M. Hereditary prenatal growth hormone defi ciency with increased tendency to growth hormone antibody formation-" A type of isolated growth hormone defi ciency ". Acta Pediatr Scand (Suppl) 1971;60: 607.
3. Ranke MB. Treatment of growth hormone insensitivity syndrome (GHIS) with insulin-like growth factor (IGF-I). Bailliè res Clin Endocrinol Metab 1996;10:401-10. (Pubitemid 26258121)
4. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE, GH Insensitivity Syndrome Collaborative Group. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I defi ciency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007;92:902-10. (Pubitemid 46465661)
5. Laron Z. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity). Pediatr Endocrinol Rev 2008;5:766-71. (Pubitemid 351462140)
6. Backeljauw PF, Underwood LE, GHIS Collaborative Group. Growth hormone insensitivity syndrome. Therapy for 6.5-7. 5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001;86:1504-10. (Pubitemid 32374895)
7. Laron Z, Lilos P, Klinger B. Growth curves for Laron syndrome. Arch Dis Child 1993;68:768-70. (Pubitemid 23199864)
8. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:752-62.
9. Mul D, Wit JM, Oostdijk W, Van den Broeck J, on behalf of the Dutch Advisory Group on Growth Hormone. The effect of pubertal delay by GnRH agonist in GH-defi cient children on fi nal height. J Clin Endocrinol Metab 2001;86:4655-6. (Pubitemid 33020503)
10. Mericq M V, Eggers M, Avila A, Cutler GB Jr, Cassorla F. Near fi nal height in pubertal growth hormone (GH)-defi cient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial. J Clin Endocrinol Metab 2000;85:569-73. (Pubitemid 32273636)
11. van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM. Reference data for bone density and body composition measured with dual energy X-ray absorp-tiometry in white children and young adults. Arch Dis Child 2002;87:341-7.
12. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170-9.
13. Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995;73:25-9.
14. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423-41.
15. Woods KA, Savage MO. Laron syndrome: typical and atypical forms. Bailliè res Clin Endocrinol Metab 1996;10:371-87. (Pubitemid 26258119)
16. Messina MF, Arrigo T, Valenzise M, Ghizzoni L, Caruso-Nicoletti M, et al. Long-term auxological and pubertal outcome of patients with hereditary insulin-like growth factor-I defi ciency (Laron and growth hormone-gene deletion syndrome) treated with recombinant human insulin-like growth factor-I. J Endocrinol Invest 2011;34:292-5.
17. Messina MF, De Luca F, Wasniewska M, Valenzise M, Lombardo F, et al. Final height in isolated GH defi ciency type 1A: effects of 5-year treatment with IGF-I. Eur J Endocrinol 2001;144:379-83. (Pubitemid 32409590)
18. Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, Diamond FB Jr, Rosenfeld RG. Growth hormone receptor defi ciency in Ecuador: clinical and biochemical phenotype in two populations. J Clin Endocrinol Metab 1993;76:417-23. (Pubitemid 23073066)
19. Joss EE, Temperli R, Mullis PE. Adult height in constitutionally tall stature: accuracy of fi ve different height prediction methods. Arch Dis Child 1992;67:1357-62.
20. Laron Z, Klinger B. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol 1998;138:176-80. (Pubitemid 28131095)
21. Drop SL, De Waal WJ, De Muinck Keizer-Schrama SM. Sex steroid treatment of constitutionally tall stature. Endocr Rev 1998;19:540-58. (Pubitemid 28467710)